在患有左心室辅助器件的患者中使用类似葡萄糖-1受体激活剂
Ramzi Ibrahim1, Hoang Nhat2, Mahmoud Abdelnabi1
1Division of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona, USA.
ESC heart failure
|October 13, 2025
概括
类似葡萄糖-1受体激动剂 (GLP1-RAs) 可能会改善左心室辅助器件 (LVAD) 患者的治疗结果. GLP1-RA治疗与更高的心脏移植率和较少的心力衰竭住院病例有关.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医疗器械 医疗器械
背景情况:
- 左心室辅助器件 (LVAD) 对于晚期心力衰竭 (HF) 是至关重要的.
- 肥胖和糖尿病复杂化了LVAD的结果.
- 类似葡萄糖-1受体激动剂 (GLP1-RAs) 已显示出心血管方面的益处,但它们在LVAD患者中的使用尚未得到充分研究.
研究的目的:
- 评估GLP1-RA治疗与LVAD患者心血管结果之间的关联.
- 研究GLP1-RAs对LVAD接受者的心脏移植率,HF住院,死亡率和心血管事件的影响.
主要方法:
- 这是一项回顾性队列研究,利用来自98个医疗保健机构的TrinetX数据库.
- 成年LVAD接受者被分为GLP1-RA使用者和非使用者.
- 倾向性得分匹配 (1:1) 均衡的患者人口统计学,并发症和实验室数据. 用后勤回归分析了结果.
主要成果:
- 该研究包括1036名LVAD接受者 (518名GLP1-RA使用者,518名匹配的非使用者).
- GLP1-RA使用者的心脏移植率显著上升 (18.9%与8.5%相比; aOR 2.514).
- GLP1-RA使用者经历的急性心力衰竭事件较少 (55.6%与68.9%相比; aOR 0.565) 和所有原因的住院治疗 (62.5%与75.3%相比; aOR 0.548).
结论:
- 晚期HF患者的GLP1-RA治疗与LVADs与心脏移植率的改善有关.
- 在LVAD接受者中,GLP1-RA的使用可能会减少住院和急性心力衰竭事件.
- 需要进一步的研究来证实这些发现并探索机制.
相关概念视频
01:24Glucagon-like Receptor Agonists
841
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
841
01:29Cardiomyopathy V: Interprofessional Care
338
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
338
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:22Heart Failure VI: Adjunct Therapies
255
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
255
01:30Heart Failure V: Medical Management
218
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
218
01:23Dipeptidyl Peptidase 4 Inhibitors
587
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
587